10.1093/pch/19.10.515 31 DubernB.Lubrano-BerthelierC.MencarelliM.ErsoyB.FrelutM.-L.BouglD.et al (2008)
Damluji, MD, PhD, MBA Published Mar 29, 2025 The SOUL trial, published in The New England Journal of Medicine on March 29, 2025, provides new evidence that once-daily oral semaglutide reduces the risk of major adverse cardiovascular events in adults with type 2 diabetes and a history of atherosclerotic cardiovascular disease, chronic kidney disease, or both
What to expect at each dose level 1mg (weeks 1-4): Mild to moderate nausea in 15-25% of users
What that phrase does not mean is illegal, and it does not automatically mean unsafe
Semaglutide activates GLP-1 receptors involved in appetite, glucose-dependent insulin release and stomach emptying
E.GalluccioM.KandasamyR